These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 21821697)

  • 21. Use of the mouse vas deferens to determine mu, delta, and kappa receptor affinities of opioid antagonists.
    Cohen ML; Mendelsohn LG; Mitch CH; Zimmerman DM
    Receptor; 1994; 4(1):43-53. PubMed ID: 8038706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antidepressant-like effects of the novel kappa opioid antagonist MCL-144B in the forced-swim test.
    Reindl JD; Rowan K; Carey AN; Peng X; Neumeyer JL; McLaughlin JP
    Pharmacology; 2008; 81(3):229-35. PubMed ID: 18176093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats.
    Broom DC; Jutkiewicz EM; Folk JE; Traynor JR; Rice KC; Woods JH
    Psychopharmacology (Berl); 2002 Oct; 164(1):42-8. PubMed ID: 12373418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mu-opioid receptor subtype is required for the anorectic effect of an opioid receptor antagonist.
    Zhang J; Frassetto A; Huang RR; Lao JZ; Pasternak A; Wang SP; Metzger JM; Strack AM; Fong TM; Chen RZ
    Eur J Pharmacol; 2006 Sep; 545(2-3):147-52. PubMed ID: 16876155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes.
    Emmerson PJ; Liu MR; Woods JH; Medzihradsky F
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1630-7. PubMed ID: 7996478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stress-Induced Reinstatement of Nicotine Preference Requires Dynorphin/Kappa Opioid Activity in the Basolateral Amygdala.
    Nygard SK; Hourguettes NJ; Sobczak GG; Carlezon WA; Bruchas MR
    J Neurosci; 2016 Sep; 36(38):9937-48. PubMed ID: 27656031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine.
    Negus SS; Burke TF; Medzihradsky F; Woods JH
    J Pharmacol Exp Ther; 1993 Nov; 267(2):896-903. PubMed ID: 8246165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.
    Knoll AT; Meloni EG; Thomas JB; Carroll FI; Carlezon WA
    J Pharmacol Exp Ther; 2007 Dec; 323(3):838-45. PubMed ID: 17823306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ARD-353 [4-((2R,5S)-4-(R)-(4-diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic acid], a novel nonpeptide delta receptor agonist, reduces myocardial infarct size without central effects.
    Watson MJ; Holt JD; O'Neill SJ; Wei K; Pendergast W; Gross GJ; Gengo PJ; Chang KJ
    J Pharmacol Exp Ther; 2006 Jan; 316(1):423-30. PubMed ID: 16188952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
    Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
    J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
    Valenzano KJ; Miller W; Chen Z; Shan S; Crumley G; Victory SF; Davies E; Huang JC; Allie N; Nolan SJ; Rotshteyn Y; Kyle DJ; Broglé K
    J Pharmacol Exp Ther; 2004 Aug; 310(2):783-92. PubMed ID: 15054115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
    Zernig G; Burke T; Lewis JW; Woods JH
    J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation.
    Melief EJ; Miyatake M; Carroll FI; Béguin C; Carlezon WA; Cohen BM; Grimwood S; Mitch CH; Rorick-Kehn L; Chavkin C
    Mol Pharmacol; 2011 Nov; 80(5):920-9. PubMed ID: 21832171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
    Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
    Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Species differences in the effects of the κ-opioid receptor antagonist zyklophin.
    Sirohi S; Aldrich JV; Walker BM
    Alcohol; 2016 Mar; 51():43-9. PubMed ID: 26992699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism.
    Ross NC; Reilley KJ; Murray TF; Aldrich JV; McLaughlin JP
    Br J Pharmacol; 2012 Feb; 165(4b):1097-108. PubMed ID: 21671905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay.
    Romero DV; Partilla JS; Zheng QX; Heyliger SO; Ni Q; Rice KC; Lai J; Rothman RB
    Synapse; 1999 Nov; 34(2):83-94. PubMed ID: 10502307
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.